Pfizer Advances Zavegepant Nasal Spray in China with Phase 3 Trial Launch Amid $11.6B Biohaven Acquisition

On August 10, the official website of the Chinese Drug Clinical Trial Registration and Information Disclosure Platform showed that Pfizer had initiated a Phase 3 study in Asian adults to evaluate the efficacy and safety of zavegepant nasal spray for the acute treatment of migraine. Nasal spray Zavegepant has been approved for the treatment of migraine. Zavegepant is a third-generation, high-affinity, highly selective small-molecule CGRP receptor antagonist developed by Biohaven Pharmaceutical.